Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection

Hye Won Lee, Seung Up Kim, Oidov Baatarkhuu, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang Hyub Han, Beom Kyung Kim

Research output: Contribution to journalShort surveypeer-review

11 Citations (Scopus)


Nucleos(t)ide analogs (NUCs) are recommended when both are fulfilled in the absence of hepatocellular carcinoma (HCC) or cirrhosis; (1) elevated serum hepatitis B virus (HBV)-DNA (≥20,000 IU/mL for hepatitis B e antigen–positive chronic hepatitis B [CHB] or ≥2000 IU/mL for hepatitis B e antigen–negative CHB) and (2) serum alanine aminotransferase ≥2× upper limit of normal.1 Therefore, many patients still remain untreated. Such untreated patients have so called “minimally active CHB,” where serum HBV-DNA is persistently >2000 IU/mL and other parameters for NUCs are below the criteria.2 There have been little data concerning their prognosis.

Original languageEnglish
Pages (from-to)2808-2810.e2
JournalClinical Gastroenterology and Hepatology
Issue number13
Publication statusPublished - 2019 Dec

Bibliographical note

Funding Information:
Funding This research was in part supported by a fund (2019-ER5102-00) by Research of Korea Centers for Disease Control and Prevention. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Publisher Copyright:
© 2019 AGA Institute

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection'. Together they form a unique fingerprint.

Cite this